# Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors

> **NCT00722228** · PHASE1,PHASE2 · RECRUITING · sponsor: **Hadassah Medical Organization** · enrollment: 50 (estimated)

## Conditions studied

- Colorectal Cancer
- Ovarian Cancer
- Gastric Cancer
- Breast Cancer
- Lung Cancer
- Kidney Cancer
- Melanoma

## Interventions

- **BIOLOGICAL:** Autologous or Allogeneic tumor cells

## Key facts

- **NCT ID:** NCT00722228
- **Lead sponsor:** Hadassah Medical Organization
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2008-07
- **Primary completion:** 2025-03
- **Final completion:** 2027-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00722228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00722228, "Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00722228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*